VETINUITY
Which cats were studied for lorazepam after urethral obstruction?
This is a single prospective study in male cats with first-time urethral obstruction; cats with urolithiasis or urinary tract infection were excluded.
● ANSWER
Sourced & dated
Lorazepam for Urethral Obstruction in Cats
● WHAT'S DOCUMENTED
In a 2026 JAVMA prospective, randomized, double-blinded, placebo-controlled trial of 80 client-owned male cats with first-time urethral obstruction (72 completing), lorazepam administered for 1 month after hospitalization was associated with zero reobstruction, versus 5 recurrences, all of them in the placebo group. The difference in recurrence rate was statistically significant: 0% on lorazepam (95% CI, 0.0–10.9) versus 15.7% on placebo (95% CI, 5.2–33.7).
Study design and population
- Prospective, randomized, double-blinded, placebo-controlled study at a university teaching hospital; cats were enrolled 2021–2025.
- 80 client-owned male cats with first-time urethral obstruction; cats with urolithiasis or urinary tract infection were excluded.
- Randomization: 41 cats to lorazepam, 39 to placebo; 72 cats completed the study.
- The study drug was administered for 1 month after hospitalization.
Secondary outcomes and safety
Lower urinary tract signs were reduced in the lorazepam group during follow-up: 2 of 33 cats showed signs during days 8–15, and 1 of 31 cats during days 16–30. Ataxia was the only adverse effect that reached statistical significance, occurring in 4 of 31 cats (13%); sedation, increased appetite, and vocalization were also reported.
Authors’ conclusion
The authors concluded that lorazepam administered for 1 month after hospitalization was associated with reduced urethral obstruction recurrence and reduced lower urinary tract signs, and was found to be safe in this population.
Clinical context
This is a single prospective study in male cats with first-time urethral obstruction; cats with urolithiasis or urinary tract infection were excluded. The findings should not be extrapolated to female cats, cats with recurrent obstruction, or cats with confirmed urolithiasis or UTI.
Ask Vetinuity
For follow-up questions about the dosing regimen, safety monitoring, or incorporating lorazepam into an obstruction discharge protocol, ask the Vetinuity clinical assistant.
● SOURCES
● RELATED ANSWERS
- Bexagliflozin (Bexacat) for Feline Diabetes Mellitus
In a 2023 JVIM field trial, once-daily bexagliflozin achieved treatment success in 84% of newly diagnosed diabetic cats, but euglycemic DKA occurred in 4 of 84.
- RECOVER CPR Guidelines for Dogs
RECOVER CPR guidelines for dogs: compression rate and depth, ventilation, drug therapy, monitoring, post-arrest care, and what the 2024 update changed.
- Canine Atopic Dermatitis: Apoquel, Cytopoint, and Treatment Options
Oclacitinib cut atopic pruritus within 24 h and, at 2 mg/kg, lokivetmab separated from placebo on owner-assessed pruritus from day 1 through day 49 in pivotal RCTs; direct head-to-head evidence remains thin.
● OPEN APP
SEE HOW VETINUITY HANDLES THIS.
Vetinuity is a clinical assistant app for veterinarians. It listens to the exam, writes the SOAP note, and lists differentials, diagnostics, and treatments with journal citations beside it.
See how it works: Treatment options and drug doses, each with its journal citation, Veterinary clinical decision support while the exam is happening.
● FAQ
Can the lorazepam findings be extrapolated to every cat with obstruction?
The findings should not be extrapolated to female cats, cats with recurrent obstruction, or cats with confirmed urolithiasis or UTI.
How was the lorazepam study designed?
Prospective, randomized, double-blinded, placebo-controlled study at a university teaching hospital; cats were enrolled 2021–2025.